S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Options Trading Plan–Perfect For Beginners (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Options Trading Plan–Perfect For Beginners (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Options Trading Plan–Perfect For Beginners (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Options Trading Plan–Perfect For Beginners (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:BNTX

BioNTech (BNTX) Price Target & Analyst Ratings

$104.64
-1.79 (-1.68%)
(As of 09/22/2023 ET)
Compare
Today's Range
$104.64
▼
$106.69
50-Day Range
$98.50
▼
$125.08
52-Week Range
$95.50
▼
$188.99
Volume
470,667 shs
Average Volume
532,778 shs
Market Capitalization
$25.22 billion
P/E Ratio
5.87
Dividend Yield
N/A
Price Target
$158.69
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BioNTech Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$158.69
51.66% Upside
High Prediction$260.00
Average Prediction$158.69
Low Prediction$116.00
TypeCurrent
9/24/22 to 9/24/23		1 Month Ago
8/25/22 to 8/25/23		3 Months Ago
6/26/22 to 6/26/23		1 Year Ago
9/24/21 to 9/24/22
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$158.69$158.69$169.64$234.46
Predicted Upside51.66% Upside36.11% Upside33.51% Upside27.31% Upside
Get BioNTech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.


BNTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.66
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside51.66% Upside1,391.31% Upside629.68% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/28/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$180.00+50.14%
8/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$119.00 ➝ $116.00+16.85%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$124.00+13.23%
5/18/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$135.00 ➝ $120.00+14.12%
5/17/2023Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$165.00 ➝ $170.00+60.98%
4/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral$142.00 ➝ $128.00+0.23%
3/31/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral$168.00 ➝ $153.00+24.83%
3/28/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$191.00 ➝ $203.00+64.24%
3/28/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Perform$145.00 ➝ $130.00+5.18%
3/28/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Chris Shibutani
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetNeutral$156.00 ➝ $140.00+13.82%
3/28/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Zhiqiang Shu
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target$260.00+111.38%
3/28/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Akash Tewari
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target$145.00+17.31%
3/27/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$239.00 ➝ $194.00+56.96%
(Data available from 9/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BNTX Price Target - Frequently Asked Questions

What is BioNTech's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for BioNTech stock is Moderate Buy based on the current 5 hold ratings and 5 buy ratings for BNTX. The average twelve-month price prediction for BioNTech is $158.69 with a high price target of $260.00 and a low price target of $116.00. Learn more on BNTX's analyst rating history.

Do Wall Street analysts like BioNTech more than its competitors?

Analysts like BioNTech less than other Medical companies. The consensus rating score for BioNTech is 2.50 while the average consensus rating score for medical companies is 2.66. Learn more on how BNTX compares to other companies.

Does BioNTech's stock price have much upside?

According to analysts, BioNTech's stock has a predicted upside of 34.76% based on their 12-month price targets.

What analysts cover BioNTech?

BioNTech has been rated by HC Wainwright, HSBC, and Morgan Stanley in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:BNTX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -